56-cessation-database

The organising principle of the substrate is the Universal Cessation Force (UCF) family — six mechanistic forces applied across nine substance and dual-diagnosis categories, cross-referenced against ten companion research projects from the inventor’s health portfolio. Layered above the UCF matrix are eight doctor-grade clinical modules: an objective withdrawal test (the UWI), a six-panel blood-work protocol, detection windows for nineteen substances, a fourteen-nutrient toxicology reference with a drug–nutrient interaction matrix, a precision dosing module, a non-chemical pain management module, a Cessation Completion Certificate framework, and an individualised Resolution Computation Engine. A public-knowledge chemistry-comparison chart benchmarks eight FDA-approved cessation compounds against the UCF substrate. A twenty-five-event historical timeline and ten forward-looking AI-generated predictions anchor the substrate in the trajectory of cessation medicine. A Chemical Cooker (Project 16) recipe bridge ships alongside — seven ready-to-run UCF-4 elemental-repair recipes plus G-code, schema-conformant to the published Cooker recipe schema.

The thesis, in the inventor’s own words: “Time is a prayer. Cessation is time work. Every receptor system heals on a measurable timeline. Every day of abstinence is a physical prayer to the future self you are becoming. The molecules do not know your name. The receptors do not know your story. But they know time. And they answer.”

The addiction crisis is a category emergency. The U.S. opioid crisis kills 80,000+ Americans per year (design-target figure from published mortality categories). Global addiction economic burden exceeds USD $600B per year in the U.S. alone (aggregate across healthcare, productivity, and criminal-justice cost centres). Existing cessation pharmacotherapy relies on a handful of aging molecules — varenicline, bupropion, cytisine, naltrexone, acamprosate, disulfiram, lofexidine, NAC — each with modest efficacy and meaningful side-effect profiles. The molecule pipeline is thin. Big pharma has largely exited addiction molecule design.

Non-chemical cessation is the emerging category. Digital therapeutics, nutritional neuroscience, exercise medicine, sleep medicine, and gut-microbiome interventions each carry isolated evidence bases. No one has assembled them into a unified substrate. Cessation Alchemy Data is that assembly. Dual-diagnosis (substance-induced psychosis in LSD, HPPD, cannabis, and stimulant use) is the underserved gap between addiction medicine and psychiatry, and UCF-6 is the substrate for that gap.

The UCF framework is the organising principle. Six mechanistic forces, each with a distinct mechanism-of-action principle, drive cessation across every substance category. The forces are additive to any existing cessation pharmacotherapy and open novel R&D and product-line pathways.

Full 6-UCF protocols are delivered for nine distinct categories. Each protocol identifies the hijacked receptor system, withdrawal timeline, medical warnings where applicable, and the precise UCF stack.

The single hardest question in recovery is: am I healed yet? Standard cessation medicine has never had an objective answer. The UWI is the test the inventor wished he had. Ten domains, each scored 0–4, total 0–40. Trackable daily during acute withdrawal, weekly during post-acute, monthly during late recovery.

The ten UWI domains are: physical symptoms, sleep, autonomic function, appetite, mood, cognitive function, cravings, anhedonia, social function, and substance-thought autonomy.

Objective criteria for the recovery discharge summary that addiction medicine has lacked. Certificate eligibility requires: UWI ≤4 sustained for thirty days + a negative urine screen + a negative hair screen (ninety-day look-back) + normal blood-work panels + the substance-specific minimum abstinence time. When met, the substrate produces a signed completion milestone — a documented endpoint that recovery culture has historically lacked.

Detection windows across urine, blood, saliva, hair, EtG, and breath for nineteen substance categories. Includes a false-positive avoidance list — poppy seeds → opiate positive; hemp seeds and CBD → THC positive; pseudoephedrine, bupropion, and trazodone → amphetamine positive; kombucha and hand sanitiser → EtG positive — and clearance-test scheduling at 30 / 60 / 90 days of abstinence to support Completion Certificate issuance.

Doctor-grade safety reference for every UCF-4 nutrient intervention. Each of the fourteen nutrient entries includes RDA, UL, therapeutic range, toxic threshold, overdose symptoms, contraindications, form bioavailability, drug interactions, and rescue protocols. Values are public-domain from the Institute of Medicine / National Academy of Medicine Dietary Reference Intakes.

A ten-row Drug–Nutrient Interaction Matrix covers critical combinations:

Nine intervention entries with acute-withdrawal dose, maintenance dose, blood-level target, form selection guidance, timing, onset, and duration-of-use. Renal adjustments are eGFR-based and hepatic adjustments are Child-Pugh-based. A baseline lab set is specified for intake plus follow-up intervals: weekly during acute withdrawal, biweekly-to-monthly during stabilisation, quarterly during maintenance.

Cessation is a state of high pain. Standard programs fail because pain drives relapse. This module treats pain as the primary clinical challenge, with seven substance-specific pain profiles (mechanism, VAS severity, timeline, clinical-scale reference — CIWA-Ar for alcohol, COWS for opioid, CWS for cannabis) and nineteen non-chemical pain interventions across physical, psychic, and sleep domains. Each intervention specifies mechanism, dose or duration, cost range, and evidence citation.

The product does not merely browse — it computes a resolution. The engine converts patient state into an individualised weekly cessation plan.

The Complete tier includes the algorithmic specification of the engine. The buyer implements the engine within their platform (EHR module, DTx application, clinical decision-support surface). The substrate provides the deterministic logic; the buyer provides the software surface.

Eight FDA-approved cessation compounds are benchmarked side-by-side against the UCF substrate. Each entry includes molecular formula, mechanism class, target substance, design-target efficacy, black-box warnings, typical side effects, cost range, duration, and UCF overlap analysis.

Positioning is additive, not competitive: the UCF substrate does not displace existing pharmacotherapy. It occupies the adjacent space — what to do besides the drug, when the drug is contraindicated, or when the drug has failed.

Twenty-five-event historical timeline from 1935 (AA founding) through 2026 (this substrate). Milestones cited include: nicotine polacrilex (1984), transdermal nicotine patch (1991), naltrexone alcohol indication (1994), bupropion smoking-cessation indication (1997), acamprosate FDA approval (2004), varenicline FDA approval (2006), Vivitrol opioid use disorder indication (2010), reSET digital therapeutic FDA authorisation (2017), lofexidine FDA approval (2018), reSET-O OUD digital therapeutic (2018), psilocybin Phase 2 signals (2020), NAC cannabis-cessation trials (2023), GLP-1 off-label observations (2024), through to Project 56 (2026).

Strategic counsel is delivered for the following audience segments: pharma R&D teams, digital-therapeutics builders, CROs and academic researchers, clinicians and addiction-medicine specialists, and inventor-level counsel on pricing, forward compatibility, and category positioning. Five documented failure modes are catalogued so acquirers can steer around them from day one.

The substrate ships with a Chemical Cooker recipe bridge that converts each UCF-4 Elemental Repair formulation into Chemical Cooker-native recipe JSON plus ready-to-run G-code. A Chemical Cooker owner (Project 16, separately available) can natively load and physically prepare the seven UCF-4 blends. The bridge emits schema-conformant files only — no proprietary Cooker code is imported or copied — and IP for both projects is retained by the inventor across all tiers.

The recipe schema followed is the published 16-chemical-cooker/platform/lite_alchemy/schema.json. Default deck positions (reservoir_1…4, well_1, well_2, waste) are supplied and may be overridden in the Cooker platform config. Compatibility version is 1.0 (2026-07-03).

The substrate is scaffolded against the inventor’s health-research portfolio. Each companion is a separate acquisition through cri-one.com/store and is not conveyed with Project 56 at any tier.

Design-target aggregate market figures from public category estimates; not investment advice.

An interactive Python shell for querying the substrate and running the Resolution Computation Engine.

Interactive commands include anchor, forces, protocol <s>, uwi, blood, drugtest [s], compute <s> <days> <uwi>, pain [s], tox [n], dose [n], interactions, chem, history, predictions, counsel, tiers, full, and quit. Example: compute opioids 45 22 returns the individualised weekly UCF stack, precision doses, drug-test schedule, days remaining to Completion Certificate eligibility, and receptor recovery timeline for a patient 45 days into opioid cessation with a UWI of 22 (post-acute severe).

Christopher Gabriel Brown
1341 Wellington Cove, Lawrenceville, GA 30043-5255, USA
Email: crioneaka@outlook.com
Store: cri-one.com/store

This package ships on a single Blu-ray disc, posted to the delivery address on your order. The archive on the disc is AES-256 encrypted; the passphrase is sent separately, by email, once the disc is despatched — so the disc alone is of no use to anyone who intercepts it.

Discs are despatched by tracked, signed-for post. Allow 5 business days for mastering and verification before despatch.

© 2026 Christopher Gabriel Brown. All rights reserved. Patent-pending.
All performance figures are design targets, not measured guarantees.
Available exclusively to buyers incorporated, headquartered, and primarily operating in the United States. USD only.
Communication by email and postal mail only — no phone calls, no brokers, no intermediaries.